CA2521407A1 - Agents medicamenteux polymeres pour le traitement des affections de type fibrose - Google Patents

Agents medicamenteux polymeres pour le traitement des affections de type fibrose Download PDF

Info

Publication number
CA2521407A1
CA2521407A1 CA002521407A CA2521407A CA2521407A1 CA 2521407 A1 CA2521407 A1 CA 2521407A1 CA 002521407 A CA002521407 A CA 002521407A CA 2521407 A CA2521407 A CA 2521407A CA 2521407 A1 CA2521407 A1 CA 2521407A1
Authority
CA
Canada
Prior art keywords
poly
agent
polymer
acid
peg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002521407A
Other languages
English (en)
Inventor
James M. Pachence
Benjamin A. Belinka
Charles L. Putnam
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vectramed Inc
Original Assignee
Vectramed Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vectramed Inc filed Critical Vectramed Inc
Publication of CA2521407A1 publication Critical patent/CA2521407A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A61K31/787—Polymers containing nitrogen containing heterocyclic rings having nitrogen as a ring hetero atom
    • A61K31/79—Polymers of vinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Surgery (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA002521407A 2003-03-31 2004-03-30 Agents medicamenteux polymeres pour le traitement des affections de type fibrose Abandoned CA2521407A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US45844903P 2003-03-31 2003-03-31
US60/458,449 2003-03-31
US79013604A 2004-03-02 2004-03-02
US10/790,136 2004-03-02
PCT/US2004/009919 WO2004089311A2 (fr) 2003-03-31 2004-03-30 Agents medicamenteux polymeres pour le traitement des affections de type fibrose

Publications (1)

Publication Number Publication Date
CA2521407A1 true CA2521407A1 (fr) 2004-10-21

Family

ID=33162191

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002521407A Abandoned CA2521407A1 (fr) 2003-03-31 2004-03-30 Agents medicamenteux polymeres pour le traitement des affections de type fibrose

Country Status (4)

Country Link
EP (1) EP1608380A2 (fr)
JP (1) JP2006522140A (fr)
CA (1) CA2521407A1 (fr)
WO (1) WO2004089311A2 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602004032553D1 (de) * 2003-09-05 2011-06-16 Gen Hospital Corp Polyacetal-arzneimittelkonjugate als freisetzungssystem
US20050106230A1 (en) * 2003-11-17 2005-05-19 Young Janel E. Drug-enhanced adhesion prevention
AU2012200202B2 (en) * 2004-03-10 2013-09-05 Ethicon, Inc. Drug-enhanced adhesion prevention
US9393315B2 (en) 2011-06-08 2016-07-19 Nitto Denko Corporation Compounds for targeting drug delivery and enhancing siRNA activity
WO2008075366A2 (fr) * 2006-12-20 2008-06-26 Medwell Laboratories Ltd. Nouveaux conjugués d'acides gras poly-insaturés avec des amines et utilisations thérapeutiques de ceux-ci
KR20110102420A (ko) 2008-12-10 2011-09-16 메르사나 테라퓨틱스, 인코포레이티드 생분해성 및 생체적합성 캄토테신-중합체 접합체의 약학 제제
US10196637B2 (en) 2011-06-08 2019-02-05 Nitto Denko Corporation Retinoid-lipid drug carrier
EP2998289B1 (fr) * 2011-06-08 2019-08-07 Nitto Denko Corporation Composés pour cibler l'administration de médicaments et renforcer l'activité arnsi
TWI658830B (zh) 2011-06-08 2019-05-11 日東電工股份有限公司 Ｈｓｐ47表現調控強化用類視色素脂質體
US9011903B2 (en) 2011-06-08 2015-04-21 Nitto Denko Corporation Cationic lipids for therapeutic agent delivery formulations

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5372807A (en) * 1990-05-14 1994-12-13 University Of Medicine And Dentistry Of New Jersey Polymers containing antifibrotic agents, compositions containing such polymers, and methods of preparation and use

Also Published As

Publication number Publication date
JP2006522140A (ja) 2006-09-28
WO2004089311A3 (fr) 2004-12-16
WO2004089311A2 (fr) 2004-10-21
EP1608380A2 (fr) 2005-12-28

Similar Documents

Publication Publication Date Title
DE69425577T2 (de) Multifunktionelle organische polymere
US6517824B1 (en) Polymer compositions comprising antifibrotic agents, and methods of treatment, pharmaceutical compositions, and methods of preparation therefor
US5482925A (en) Complexes of nitric oxide with cardiovascular amines as dual acting cardiovascular agents
CA2416126C (fr) Composites bioabsorbables d'acide hyaluronique derive
JP5063108B2 (ja) 心筋疾患症状を治療するための方法および組成物
US20110250284A1 (en) Nanoparticles for Use as Synthetic Platelets and Therapeutic Agent Delivery Vehicles
JP2003501393A (ja) 心臓血管細胞増殖を阻害するための方法および組成物
US11975109B2 (en) Methods for targeted delivery of agents to degraded elastic fibers
US6472379B1 (en) Angiogenesis inhibition
JP2002155137A (ja) 酸化窒素生成ヒドロゲル物質
Pertici et al. Inputs of macromolecular engineering in the design of injectable hydrogels based on synthetic thermoresponsive polymers
CA2521407A1 (fr) Agents medicamenteux polymeres pour le traitement des affections de type fibrose
Wei et al. A combination of hybrid polydopamine-human keratinocyte growth factor nanoparticles and sodium hyaluronate for the efficient prevention of postoperative abdominal adhesion formation
JP2007529554A (ja) 多価リガンド結合糖質ポリマーを用いた組成物、および該組成物による転移腫瘍の標的療法
JP2003504312A (ja) 生物学的に活性な材料
US6326021B1 (en) Biocompatible polymeric delivery systems having functional groups attached to the surface thereof
US20230183361A1 (en) Extended local release of antibodies
JP2021529837A (ja) 低酸素関連組織損傷を治療するための投薬レジメン
RU2792146C2 (ru) Конъюгат дексаметазона с синтетическим статистическим полипептидом
US20030186869A1 (en) Polymer compositions comprising antifibrotic agents, and methods of treatment, pharmaceutical compositions, and methods of preparation therefor
US20190274975A1 (en) Nanoparticles for stimulating elastogenesis
Zhong Injectable hydrogels functionalized with VHH for neutralizing inflammatory cytokines
Bouma et al. Novel Therapetic Delivery Systems
WO2022146925A1 (fr) Libération locale étendue d'anticorps
Baumann A Composite Polymeric Drug Delivery System for Treatment of Spinal Cord Injury

Legal Events

Date Code Title Description
FZDE Dead